The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab

作者全名："Gou, Bin; Yang, Ping; Feng, Jinzhou; Li, Yongmei; Huang, Gen; Shi, Jiafeng; Wen, Lu; Guo, Xiuming; Zheng, Peng; Yu, Gang"

作者地址："[Gou, Bin; Yang, Ping; Feng, Jinzhou; Huang, Gen; Shi, Jiafeng; Wen, Lu; Guo, Xiuming; Zheng, Peng; Yu, Gang] Chongqing Med Univ, Dept Neurol, Affiliated Hosp 1, Chongqing, Peoples R China; [Li, Yongmei] Chongqing Med Univ, Dept Radiol, Affiliated Hosp 1, Chongqing, Peoples R China; [Yu, Gang] Youyi Rd 1, Chongqing, Peoples R China"

通信作者："Yu, G (通讯作者)，Youyi Rd 1, Chongqing, Peoples R China."

来源：JOURNAL OF NEUROIMMUNOLOGY

ESI学科分类：NEUROSCIENCE & BEHAVIOR

WOS号：WOS:000926706000001

JCR分区：Q2

影响因子：2.9

年份：2023

卷号：376

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：Neuromyelitis optica spectrum disorders; Aquaporin-4 antibody; Myelin-oligodendrocyte glycoprotein antibody; Anti-CD20 antibody; Ofatumumab

摘要："Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune demyelinating disease with IgG against aquaporin 4 (AQP4) in more than two thirds of patients. Anti-myelin-oligodendrocyte glycoprotein (MOG) antibody is found in some AQP4-negative NMOSD patients and MOG antibody-associated disease (MOGAD) is thought to be distinct from NMOSD. Due to the high disabling nature of NMOSD, treatment strategy on first attack is crucial for good prognosis. Rituximab (RTX), an anti-CD20 monoclonal antibody (mAb), is the first-line treatment for NMOSD. However, RTX can be limited by the relatively high rate of systemic allergic reaction. Herein, we reported a rare case of AQP4 and MOG-IgG double positive NMOSD patient effectively and safely treated with ofatumumab (OFA), a novel fully humanized anti-CD20 mAb."

基金机构：　

基金资助正文：